Sarah Kelly serves as vice president of Corporate Development at Centrexion Therapeutics, where she leads business development strategy, licensing efforts, portfolio prioritization, and commercial strategy. She brings more than two decades of experience in business development, all aspects of commercialization, and product planning across emerging biotech, global pharmaceutical companies, and medical devices.
Sarah has held senior leadership roles at companies including Amgen, Agilent Technologies, Turning Point Therapeutics, and Spectrum Pharmaceuticals. Sarah was Vice President of Sales at Turning Point Therapeutics before the company was acquired by BMS. She held multiple commercial leadership roles at Amgen, including roles in brand marketing, sales leadership, and market access strategy. Sarah led the US launch team for Nplate while at Amgen, and the launch of Beleodaq at Spectrum. She also has deep expertise in companion diagnostics from her time at Agilent Technologies/DAKO, where she helped launch several industry-first co-commercialized diagnostics with partners such as Genentech, Merck and BMS.
Sarah holds an MBA from Pepperdine University and a B.A. in Business/Economics from the University of California, Santa Barbara. She also completed executive coursework in venture capital at Columbia University and finance at UCLA Extension.